tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Promising Phase 2 Results for ATH434 Boost Alterity Therapeutics’ Buy Rating
RatingsPromising Phase 2 Results for ATH434 Boost Alterity Therapeutics’ Buy Rating
8h ago
ATHE
Alterity Therapeutics presents data from ATH434 Phase 2 trial
PremiumThe Fly
Alterity Therapeutics presents data from ATH434 Phase 2 trial
6d ago
ATHE
Alterity Therapeutics to Present Promising Phase 2 Trial Results for MSA Treatment at 2025 Congress
PremiumCompany Announcements
Alterity Therapeutics to Present Promising Phase 2 Trial Results for MSA Treatment at 2025 Congress
13d ago
Alterity Therapeutics Projects $2.4 Billion Sales for MSA Drug ATH434
PremiumCompany Announcements
Alterity Therapeutics Projects $2.4 Billion Sales for MSA Drug ATH434
16d ago
Alterity Therapeutics Announces Director’s Interest Change
PremiumCompany Announcements
Alterity Therapeutics Announces Director’s Interest Change
28d ago
Alterity Therapeutics Announces Cessation of 35 Million Securities
PremiumCompany AnnouncementsAlterity Therapeutics Announces Cessation of 35 Million Securities
28d ago
Alterity Therapeutics presents ATH434-201 Phase 2 data
Premium
The Fly
Alterity Therapeutics presents ATH434-201 Phase 2 data
30d ago
ATHE
Alterity Therapeutics’ ATH434 Shows Promise in Phase 2 MSA Trial
Premium
Company Announcements
Alterity Therapeutics’ ATH434 Shows Promise in Phase 2 MSA Trial
30d ago
Alterity Therapeutics Issues Over 1.6 Billion New Shares
PremiumCompany Announcements
Alterity Therapeutics Issues Over 1.6 Billion New Shares
1M ago
Alterity Therapeutics Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Alterity Therapeutics Announces Quotation of New Securities on ASX
1M ago
Alterity Therapeutics raises A$20M in strategic placement
PremiumThe Fly
Alterity Therapeutics raises A$20M in strategic placement
1M ago
ATHE
Alterity Therapeutics Announces Major Securities Issue
PremiumCompany Announcements
Alterity Therapeutics Announces Major Securities Issue
1M ago
Alterity Therapeutics Secures A$20 Million to Advance Neurodegenerative Disease Treatment
PremiumCompany AnnouncementsAlterity Therapeutics Secures A$20 Million to Advance Neurodegenerative Disease Treatment
1M ago
Alterity Therapeutics Ltd (ADR) trading halted, news pending
Premium
The Fly
Alterity Therapeutics Ltd (ADR) trading halted, news pending
1M ago
ATHE
Alterity Therapeutics Files Annual Report with SEC
Premium
Company Announcements
Alterity Therapeutics Files Annual Report with SEC
1M ago
Alterity Therapeutics to Present Corporate Update at Biotech Showcase
PremiumCompany Announcements
Alterity Therapeutics to Present Corporate Update at Biotech Showcase
1M ago
Alterity Therapeutics Releases 2025 Corporate Governance Statement
PremiumCompany Announcements
Alterity Therapeutics Releases 2025 Corporate Governance Statement
2M ago
Alterity Therapeutics Releases Corporate Governance Statement for FY2025
PremiumCompany Announcements
Alterity Therapeutics Releases Corporate Governance Statement for FY2025
2M ago
Alterity Therapeutics Reports Revenue Growth Amid Financial Loss
PremiumCompany Announcements
Alterity Therapeutics Reports Revenue Growth Amid Financial Loss
2M ago
Alterity Therapeutics Announces Quotation of New Securities on ASX
PremiumCompany AnnouncementsAlterity Therapeutics Announces Quotation of New Securities on ASX
2M ago
Alterity Therapeutics Issues New Unlisted Options as Part of Employee Incentive Scheme
Premium
Company Announcements
Alterity Therapeutics Issues New Unlisted Options as Part of Employee Incentive Scheme
2M ago
Alterity Therapeutics Issues New Unlisted Options as Part of Employee Incentive Scheme
Premium
Company Announcements
Alterity Therapeutics Issues New Unlisted Options as Part of Employee Incentive Scheme
2M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >